Genetic variation in Interleukin-32 influence the immune response against New World Leishmania species and susceptibility to American Tegumentary Leishmaniasis

Interleukin-32 is a novel inflammatory mediator that has been described to be important in the immunopathogenesis and control of infections caused by Leishmania parasites. By performing experiments with primary human cells in vitro, we demonstrate that the expression of IL-32 isoforms is dependent o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS neglected tropical diseases 2020-02, Vol.14 (2), p.e0008029
Hauptverfasser: Dos Santos, Jéssica Cristina, Leite Quixabeira, Valéria Bernadete, Teodoro Silva, Muriel Vilela, Damen, Michelle S M A, Schraa, Kiki, Jaeger, Martin, Oosting, Marije, Keating, Samuel T, Dorta, Miriam Leandro, Alves Pinto, Sebastião, Bugalho Duarte, Fernanda, de Araújo Pereira, Ledice Inácia, Netea, Mihai G, Ribeiro-Dias, Fátima, Joosten, Leo A B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Interleukin-32 is a novel inflammatory mediator that has been described to be important in the immunopathogenesis and control of infections caused by Leishmania parasites. By performing experiments with primary human cells in vitro, we demonstrate that the expression of IL-32 isoforms is dependent on the time exposed to L. amazonensis and L. braziliensis antigens. Moreover, for the first time we show the functional consequences of three different genetic variations in the IL32 (rs4786370, rs4349147, rs1555001) modulating IL-32γ expression, influencing innate and adaptive cytokine production after Leishmania exposure. Using a Brazilian cohort of 107 American Tegumentary Leishmaniasis patients and a control cohort of 245 healthy individuals, the IL32 rs4786370 genetic variant was associated with protection against ATL, whereas the IL32 rs4349147 was associated with susceptibility to the development of localized cutaneous and mucosal leishmaniasis. These novel insights may help improve therapeutic strategies and lead to benefits for patients suffering from Leishmania infections.
ISSN:1935-2735
1935-2727
1935-2735
DOI:10.1371/journal.pntd.0008029